Navigation Links
BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Date:9/11/2008

NOVATO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global Pharmaceutical Conference in London on Thursday, September 18, 2008 at 10:35 a.m. BST.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin Announces Roll-Out of National PKU Registry
4. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Collins Stewart Growth Conference
6. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
7. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
8. BioMarin to Host Research and Development Day June 5th
9. BioMarin to Present at the Bank of America Healthcare Conference
10. BioMarin Announces First Quarter 2008 Financial Results
11. BioMarin to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will ... conference in San Francisco’s Moscone Center from February 16-18, 2016, and at the ... These latest InGaAs PIN diode standard packages feature a TO-46 metal can with active ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... is now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing ... saw clear demand for Microsoft Azure from major institutions collecting and analyzing genomic ...
(Date:2/10/2016)... Vancouver, BC (PRWEB) , ... February 09, 2016 ... ... and design services and current winner of the Highest Overall Customer Rating ... certification in all of its business units across the USA, Canada, Mexico and ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: March ... at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, Doylestown, ... (TCMC) will hold an open house for participants to learn about a new ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
Breaking Biology News(10 mins):